Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
A phase 3 trial of Taletrectinib in non-small-cell lung cancer and small-cell lung cancer, run by Nuvation Bio Inc., now recruiting.
Overview
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) is a phase 3 interventional study registered as NCT07154706 by Nuvation Bio Inc., with 180 participants planned, started 2025-08-21 and due to reach its primary completion in 2030-08-30. Interventions recorded: Taletrectinib, Placebo. Conditions listed: Non-small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialTaletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
Shares Taletrectinib, Nuvation Bio, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
Shares Taletrectinib, Nuvation Bio, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene
Shares Nuvation Bio, Non-small-cell lung cancer.
- TargetROS1
Shares Taletrectinib, Non-small-cell lung cancer.